Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Foundation Medicine, Inc. FMI
By a
The Complaint filed in this class action alleges that, during the Class Period, the Company made false and misleading statements and/or failed to disclose adverse information regarding the Company's business and prospects. Specifically, the complaint alleges that the defendants made false and/or misleading statements regarding: (i) the reimbursement process and likelihood of coverage for Foundation's tumor tests by Medicare; and (ii) the Company's financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.
On
On this news, the price of Foundation common stock fell
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares of Foundation during the Class Period you may move the Court no later than
This press release may be considered
Keywords for this news article include: Medicare, Legal Issues, Health Policy, Glancy Prongay and
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
Principal Life Insurance Co Separate Account B Files SEC Form 497, Definitive Materials: (Sept. 22, 2017)
Health Partners Plans Among 11 Medicaid Plans in Nation Awarded “Excellent” by NCQA
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News